BABESIOOSIA MYÖS EUROOPASSA!

[Bb]

Lähettäjä: Soijuv Lähetetty: 3.6.2004 11:54

Babesioosia esiintyy jonkin verran myös Euroopassa. Esim. borrelioosia sairastaville babesioosi voi aiheuttaa vakavan kroonisen sairauden.



Babesia microti Infection in Europe.
Curr Microbiol. 2004 Jun;48(6):435-7.

Meer-Scherrer L, Adelson M, Mordechai E, Lottaz B, Tilton R.

37 Flammat, Aumatt, Switzerland.

The majority of babesia infections in Europe are life-threatening and caused by Babesia divergens and B. bovis. Although Babesia microti has been detected in ticks from Switzerland, few if any cases of babesiosis have been caused by B. microti. This first reported case, diagnosed by serology, DNA detection, and microscopy, is additionally interesting because there appears to be coinfection with the Lyme disease organism, Borrelia burgdorferi.

PMID: 15170239 [PubMed - in process]

http://infection.thelancet.com/journal/ ... re.29098.1

Babesia infection in Italy

Pier Paolo Piccaluga, Giovanni Poletti, Giovanni Martinelli, and Filippo Gherlinzoni

*/No Summary Available/*
There is no summary for this article. The text below is the first paragraph of text within the article.

Our patient is a 55-year-old man who had undergone to splenectomy for Hodgkin's disease in 1980. He started chemotherapy for a diffuse large B-cell lymphoma in 1998. During chemotherapy, the patient presented with fever (39°C), confusion, severe anaemia, thrombocytopenia, haemoglobinuria, and lactate dehydrogenase, creatinine, and bilirubine elevation. He had no history of tick bites, foreign travel, or transfusion. Babesiosis was diagnosed by observing parasitic inclusions in erythrocytes on peripheral-blood smears (figure, presence of intraerythrocytic protozoa suggestive for babesia infection is outlined). Antibody titre against /Babesia divergens/ was weakly positive. Specific therapy with clindamicine (600 mg thrice daily intravenously) and quinine sulphate (650 mg thrice daily orally) was administered for 15 days. Fever resolved after 3 days of therapy; parasites disappeared from blood-smears after 6 days. The infection never recurred.

13th International Scientific Conference on Lyme Disease & Other Tick-Borne Disorders

Emphasis: Pediatrics & New Research
March 24-26, 2000 Hartford Marriott Farmington, CT, USA

Mefloquine and Artemesia: A Prospective Trial of Combination Therapy in Chronic Babesiosis

Dr. Richard Horowitz

Background:
Babesiosis has previously been regarded as a benign self-limitingillness; however recent evidence has shown that patients who are either immuno-compromised or co-infected with Borrelia burgdorferi and/or HGE are at risk for a more severe chronic disease state (Krause et al, JAMA 1996 June
5: 275(21): 1657-1666). Krause also noted persistent parasitemia after acute Babesiosis (NEJM 7/98, Vol 339, 160-165) when patients received Cleocin+Quinine (C+Q), and Horowitz described chronic persistent Babesiosis after acute treatment with Cleocin+Quinine (C+Q) and Atovaquone and Azithromycin (M+Z) (Abstract, 12th International Scientific Conference on Lyme Disease and Other Spirochetal & Tick-Borne
Disorders, April 1999, NYC), with persistence of Babesial DNA despite repeated courses of both antibiotic regimens. This report describes clinical improvement in a cohort of co-infected Lyme patients using Mefloquine (Lariam) + Artemesia (L+A) as either first-line treatment for infections with Babesia microti, or after having filled standard regimens with C+Q or M+Z.

........

Conclusion:
Mefloquine+Artemesia is a new and improved treatment regimen for chronic persistent Babesiosis. This regimen has been studied and shown to be effective in malaria (Antimalarial Activity of Mefloquine and Qinghaosu (Artemesia): Lancet, Aug 1982, 285-289), but has never been studied in patients with infections with Babesia microti, a malarial-like illness. Optimal effectiveness was seen with a 5-week cours; however certain patients were PCR positive post therapy, and needed retreatment with either a different regimen, longer course, or higher doses of L+A (2q 5-7 days), which occasionally was of clinical benefit. Treatment failures have therefore been seen with all presently available antibiotic regimens for Babesia microti and may reflect an exoerythrocytic stage of infection establishing a chronic carrier state. Further research isnecessary into the role, diagnosis, and treatment of piroplasms in co-infected Lyme patients.